Conviva Launches on Google Cloud Marketplace
Conviva, a continuous measurement analytics platform, today announced its availability on Google Cloud Marketplace, expanding its partnership with Google Cloud and enabling seamless procurement and consolidated billing through a single channel.
“We are thrilled to bring Conviva to Google Cloud Marketplace,” said Keith Zubchevich, President & CEO, Conviva. “The entire media industry is undergoing digital transformation as companies look to better leverage cloud technologies to future-proof their investments and extract faster actionable insights from their technologies, individual viewers, and audiences. We look forward to supporting Google Cloud customers by providing this one-stop-shop for purchasing Conviva through Google Cloud Marketplace.”
Conviva’s continuous measurement analytics platform delivers comprehensive measurement of the viewing experience, from individual viewers down to every second of an active session. Through one consistent and accurate data pipeline—powered by continuous sessionization and instantaneous server-side computation of real-time metrics—Conviva delivers full-census analytics into the hands of publishers for immediate actionability on real-world moments. Teams throughout publisher organizations rely on these unified and trusted insights to drive faster business decisions, optimize delivery and performance on the fly, adapt to viewer engagement in real-time, and activate experience and audience intelligence across connected systems for deeper analysis, automation, orchestration, customer care, and more.
Through the global reach of Google Cloud Marketplace, publishers across the world can now access Conviva solutions faster, accelerating the time to value for digital transformation initiatives by providing the industry’s most trusted actionable insights to drive viewer acquisition, engagement, and loyalty for their streaming media businesses.
“Google is a key strategic partner of Conviva,” said James Shears, VP of Business Development at Conviva. “In addition to our strategic partnership with Google Cloud, we are enabling Conviva customers to easily deliver data feeds directly to destinations like Google BigQuery for analysis and machine learning and we continue to develop new and innovative ways to deliver data faster into other areas of the Google Cloud ecosystem.”
“As media and entertainment companies look to unlock new opportunities in streaming, there’s a growing need for businesses to digitally transform and support a customer-centric, data-driven model that can adapt to evolving customer preferences,” said Kip Schauer, Global Head of Media and Entertainment Partnerships at Google Cloud. “We’re excited to have the Conviva platform available on the Google Cloud Marketplace to deliver customers a single source of truth across business units, enabling organizations and their teams with the actionable insights needed to support this transformation for publishers.”
For more information and to get started with Conviva, visit Conviva on Google Cloud Marketplace.
Connect with Conviva
- Visit us at Conviva.com
- Follow Conviva on LinkedIn
- We’re hiring! Join the Conviva team
About Conviva
Conviva is the continuous measurement analytics platform for streaming media. Powered by our patented Stream Sensor™, our real-time platform enables marketers, advertisers, tech ops, engineering and customer care teams to acquire, engage, monetize and retain their audiences. Conviva is dedicated to supporting brands like DAZN, Disney+, Hulu, Paramount+, Peacock, Sky, Sling TV, TED and Warner Media as they unlock the incredible opportunity in streaming media. Today our platform processes roughly 3 trillion streaming data events daily, supporting more than 500 million unique viewers watching 200 billion streams per year across 4 billion applications streaming on devices. Conviva ensures digital businesses of all sizes can stream better—every stream, every screen, every second. To learn more, visit www.conviva.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220418005051/en/
Contact information
Megan Dobransky
press@conviva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named Sitecore’s First Global Partner Under Global Elite Reseller Program8.1.2026 10:00:00 EET | Press release
Global IT Corporation FPT announced its appointment as the inaugural Global Elite Reseller under a new initiative from Sitecore that expands upon its successful Global Reseller Program. The Global Elite Reseller Program follows the launch of SitecoreAI, the next-generation digital experience platform that puts artificial intelligence at the center of marketing, unifying content, data, and personalization in one composable platform so organizations can reach, engage, and serve their audience across digital channels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107425261/en/ Representatives from FPT and Sitecore at the Global Elite Reseller signing ceremony. Under the agreement, FPT will hold exclusive reseller rights in Vietnam and non-exclusive rights across select markets in Asia and the Middle East, taking SitecoreAI to market and showing how it helps teams plan, create, and optimize digital experiences using AI as cu
Natus Sensory Appoints Arne Boye Nielsen to Board of Directors8.1.2026 09:00:00 EET | Press release
Natus Sensory, a global leader in sensory and diagnostic solutions, today announced the appointment of Arne Boye Nielsen to its Board of Directors, effective January 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107392331/en/ Arne Boye Nielsen Arne brings more than 30 years of executive leadership experience in diagnostics and medical technology, most notably as President of Demant Diagnostics, where he built and scaled the business into a global leader over three decades. During his tenure, Arne played a central role in shaping Demant Diagnostics’ long-term strategy, portfolio expansion, and international growth, establishing it as a cornerstone of Demant’s global healthcare footprint. In addition to his executive leadership background, Arne brings extensive board experience. His deep expertise across diagnostics, governance, and value creation will further strengthen Natus Sensory’s Board as the company contin
4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics8.1.2026 08:30:00 EET | Press release
4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107798042/en/ 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). The U.S. Food and Drug Administration (FDA) approval marks another strategic step in 4MB’s global clinical deployment across
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo ® in France, Denmark, Iceland, Sweden, Finland and Norway8.1.2026 08:30:00 EET | Press release
Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins.ii “This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo® to patients in France, Denmark, Iceland, Sweden, Finland and Norway,” says Thibault Crosnier Leconte, AVP & Managing Director at Organon Northwest Europe. “By offering a new treatment option for patients who cannot tolerate statins, we are helping to close a persistent gap in cardiovascular care—one that disproportionately affects women – whilst reinforcing our mission to deliver impactful treatments for a healthier every day.” Cardiovascular disease i
Azafaros to Present at J.P. Morgan’s 44 th Annual Healthcare Conference8.1.2026 08:00:00 EET | Press release
Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that it will present at J.P. Morgan’s 44th Annual Healthcare Conference on Thursday, January 15. The company’s presentation will begin at 9:30 am PT/12:30 am ET/6:30 am CET. The presentation will focus on the company’s lead product, nizubaglustat, a potential treatment for rare lysosomal storage disorders with neurological involvement including GM1/GM2 gangliosidoses and Niemann-Pick type C disease ((NPC). Two pivotal Phase 3 studies investigating nizubaglustat in GM1/GM2 gangliosidoses and NPC are currently enrolling, with data expected in 2027. The studies build on positive data from a robust clinical program including the Phase 2 RAINBOW study and the PRONTO natural history study. The Phase 3 studies are financed following the company’s successful completion of €132 million series B round completed in 1H 2025. About nizubaglust
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom